Top Markets
#1 Black Phoenix Black Phoenix +333.52%
#2 Islamic Coin Islamic Coin +158.18%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +21.05%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.65%
#6 DOVU DOVU +15.63%
#7 Palladium Network Palladium Network +8.75%
#8 Pons Pons +7.99%
#9 stake.link stake.link +7.92%
#10 Movement Movement +6.59%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Rang in aandelen #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Aandeelprijs
$0.00023723
Laatst gesynchroniseerd: 2024-08-26
Marktkapitalisatie
$1.41K
Verandering (1 dag)
111.67%
Verandering (1 jaar)
0.00%
Land
FR
Handel Pharnext S.A. (ALPHA)

Categorie

Healthcare
Winst voor Pharnext S.A. (ALPHA)
Winst in Dec 2023 TTM: $-31.69M
Volgens de meest recente financiële verslagen van Pharnext S.A. bedraagt de huidige winst van het bedrijf $-31.69M. In 2022 behaalde het bedrijf een winst van $-43.29M, een daling ten opzichte van de winst van 2021, die $-38.48M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Pharnext S.A. van 2013 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-31.69M 1.28%
2023 $-31.29M -27.73%
2022 $-43.29M 12.50%
2021 $-38.48M 30.75%
2020 $-29.43M -0.92%
2019 $-29.70M 21.26%
2018 $-24.50M -15.52%
2017 $-29.00M 29.32%
2016 $-22.42M 87.83%
2015 $-11.94M -8.06%
2014 $-12.98M 1.29%
2013 $-12.82M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -16,747.05%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -6,256.06%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -9,585.74%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR